BIOCRYST PHARMACEUTICALS INC Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2011 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Biocryst Pharmaceuticals Inc quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2011 to Q4 2023.
  • Biocryst Pharmaceuticals Inc Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $437M, a 12.2% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $437M +$47.5M +12.2% Dec 31, 2023 10-K 2024-02-27
Q4 2022 $390M +$70.9M +22.2% Dec 31, 2022 10-K 2024-02-27
Q4 2021 $319M +$48M +17.7% Dec 31, 2021 10-K 2023-02-27
Q4 2020 $271M +$38.6M +16.6% Dec 31, 2020 10-K 2022-02-28
Q4 2019 $232M +$23.7M +11.4% Dec 31, 2019 10-K 2021-03-01
Q4 2018 $208M +$26M +14.3% Dec 31, 2018 10-K 2020-03-13
Q4 2017 $182M -$42.6M -18.9% Dec 31, 2017 10-K 2019-03-14
Q4 2016 $225M +$19.8M +9.67% Dec 31, 2016 10-K 2018-03-12
Q4 2015 $205M +$20.3M +11% Dec 31, 2015 10-K 2017-02-27
Q4 2014 $185M +$17.3M +10.3% Dec 31, 2014 10-K 2016-02-26
Q4 2013 $168M +$8.57M +5.39% Dec 31, 2013 10-K 2015-03-02
Q4 2012 $159M +$7M +4.61% Dec 31, 2012 10-K 2014-03-10
Q4 2011 $152M Dec 31, 2011 10-K 2013-03-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.